Showing results 1 to 3 of 3
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
2016 | 46 | |||
A phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology | 2012 | 115 | ||
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology | 2012 | 122 |